Navigation Links
Neurocrine Biosciences Reports Second Quarter 2014 Results
Date:8/6/2014

am in Tourette syndrome patients this year.

Elagolix UpdateAbbVie is currently conducting the Violet Petal Study, a Phase III study of elagolix for endometriosis.  The study is a 24-week, multinational, randomized, double-blind, placebo-controlled study designed to evaluate the safety and efficacy of elagolix in 875 women, age 18 to 49, with moderate to severe endometriosis-associated pain.  Approximately 160 sites in the United States, Puerto Rico and Canada are conducting this study which completed patient recruitment and randomization during the second quarter.

AbbVie is also conducting the second Phase III study of elagolix for endometriosis, the Solstice Study.  This study is similar in design to the Violet Petal Study and will assess 788 women, age 18 to 49, with moderate to severe endometriosis-associated pain at more than 200 sites globally.

Elagolix is also being studied for utilization in uterine fibroids.  AbbVie is conducting a Phase IIb clinical trial evaluating the change in uterine blood loss of 520 women, age 18-51, with heavy uterine bleeding due to uterine fibroids.

Conference Call and Webcast Tomorrow at 8:00AM Eastern Time
Neurocrine will hold a live conference call and webcast tomorrow at 8:00 a.m. Eastern Time (5:00 a.m. Pacific Time).  Participants can access the live conference call by dialing 866-952-1907 (US) or 785-424-1826 (International) using the conference ID: NBIX.  The call can also be accessed via the webcast through the Company's website at http://www.neurocrine.com.

If you are unable to attend the webcast and would like further information on this announcement please contact the Investor Relations Department at Neurocrine Biosciences at ir@neurocrine.com.  A replay of the conference call will be available approximately one hour after the conclusion of the call by dialing 800-839-
'/>"/>

SOURCE Neurocrine Biosciences, Inc.
Copyright©2014 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Neurocrine Biosciences Announces Conference Call and Webcast to Present First Quarter 2012 Financial Results
2. Neurocrine Biosciences Reports First Quarter 2012 Results
3. Neurocrine Biosciences to Present at the Jefferies 2012 Global Healthcare Conference
4. Neurocrine Biosciences Announces Conference Call And Webcast To Present Second Quarter 2012 Financial Results
5. Neurocrine Biosciences To Present At The Morgan Stanley Global Healthcare Conference
6. Neurocrine Biosciences Announces Conference Call and Webcast to Present Third Quarter 2012 Financial Results
7. Neurocrine Biosciences To Present At Lazard Capitalmarkets 9th Annual Healthcare Conference
8. Neurocrine Biosciences To Present At Deutsche Banks 2012 dbAccess BioFEST
9. Neurocrine Biosciences Announces Additional European And United States Patents Issued On Proprietary VMAT2 Inhibitor
10. Neurocrine Biosciences Announces Conference Call And Webcast To Present Fourth Quarter And Year-End 2012 Financial Results
11. Neurocrine Biosciences To Present At The Leerink Swann Global Healthcare Conference 2013
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/29/2015)... , May 29, 2015 A six-hour certification ... is being presented at the Cannabis World Congress & ... New York, NY .  Taking place on Wednesday, ... dedicated day of education at the leading event on the ... Led by Clover Leaf University, the first cannabis ...
(Date:5/29/2015)... May 28, 2015 Research and Markets ( ... "North America Open System MRI Market - Growth, Trends ... offering. The key players in the industry ... Siemens Healthcare and Toshiba Medical Systems ... replacing CT because of its higher sensitivity and use ...
(Date:5/29/2015)... , May 29, 2015 Eli Lilly ... Goldman Sachs 36th Annual Global Healthcare Conference on Tuesday, ... president and president, Elanco Animal Health, will participate in ... A live audio webcast will be ... investor website at http://investor.lilly.com/events.cfm . A replay of ...
Breaking Medicine Technology:Cannabis Business Certification and Career Workshops Presented at New York Trade Show & Conference 2Cannabis Business Certification and Career Workshops Presented at New York Trade Show & Conference 3Cannabis Business Certification and Career Workshops Presented at New York Trade Show & Conference 4North America Open System MRI Market 2014-2019 with GE, Hitachi Medical, Philips Healthcare, Siemens Healthcare and Toshiba Medical Dominating 2Lilly to Participate in Goldman Sachs Global Healthcare Conference 2
... AutoGenomics, a leader in,developing automated molecular testing solutions, ... submitted to the FDA for 510(k) clearance,late last ... Medical,School-Partners HealthCare Center for Genetics and Genomics (HPCGG). ... prescribed to help prevent,blood clots. With more than ...
... against osteoporosis-related fractures, including spine and hip, - Reclast reduced spine ... placebo in study published in New England Journal of Medicine, - Unique once-yearly ... ... - Osteoporotic fractures affect one in two women over 50(1) and are ...
Cached Medicine Technology:Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity 2Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis 2Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis 3Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis 4Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis 5Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis 6
(Date:5/30/2015)... Thousands of aesthetic industry professionals converged ... by the American Society for Aesthetic Plastic Surgery (ASAPS). ... Zeltiq, the parent company of one of the fastest ... blazing growth, the one-of-a-kind device just sold its 2 ... currently in the news for gaining the FDA’s stamp ...
(Date:5/30/2015)... New York (PRWEB) May 30, 2015 ... pay $100 million in punitive and compensatory damages ... plaintiff who suffered serious complications following implantation of ... to a verdict rendered on May 28th in ... million in compensatory damages after the jury found ...
(Date:5/30/2015)... May 30, 2015 At 73 years old, ... vibrant health , which she attributes to a lifetime ... of good nutrition with the release of her new book ... Xlibris AU). , “Cook for Health and Longevity” features a ... and mostly organic food . It is designed to ...
(Date:5/30/2015)... May 30, 2015 Key Housing, a ... proud to announce their June 2015 featured apartment community: ... in San Francisco, Key Housing is helping those people ... what is one of the tightest apartment markets in ... posting, and understandably anyone who requires temporary San Francisco ...
(Date:5/30/2015)... Vegas, Nevada (PRWEB) May 30, 2015 ... treatment of acne scars, large pores, deep wrinkles, stretch ... a licensed medical professional, such as Dr. F. Victor ... some of the clinical trials in Las Vegas. This ... SmartScan technology into a system that delivers proven results ...
Breaking Medicine News(10 mins):Health News:Dr. Paul Vitenas Meets with Zeltiq President and CEO in Montreal 2Health News:Dr. Paul Vitenas Meets with Zeltiq President and CEO in Montreal 3Health News:Boston Scientific Transvaginal Mesh Lawsuit Trial Ends With $100 Million Verdict 2Health News:Boston Scientific Transvaginal Mesh Lawsuit Trial Ends With $100 Million Verdict 3Health News:Boston Scientific Transvaginal Mesh Lawsuit Trial Ends With $100 Million Verdict 4Health News:Lynn Kendall Shows How to ‘Cook for Health and Longevity’ 2Health News:Lynn Kendall Shows How to ‘Cook for Health and Longevity’ 3Health News:San Francisco Corporate Housing Leader Key Housing Designates 388 Beale Street as Featured Community for June 2Health News:San Francisco Corporate Housing Leader Key Housing Designates 388 Beale Street as Featured Community for June 3Health News:Announcing Ground-Breaking Technology for Anti-Aging, FDA Approved, Venus Viva. 2Health News:Announcing Ground-Breaking Technology for Anti-Aging, FDA Approved, Venus Viva. 3
... 12 Weight Watchers,International, Inc. (NYSE: WTW ) ... cash dividend of $0.175 per share, which corresponds,to an ... dividend will,be payable on July 11, 2008 to shareholders ... 2008., About Weight Watchers International, Inc., Weight ...
... to more accurately diagnose and treat heart failure ... Syntermed, an Atlanta-based nuclear medicine imaging and informatics ... (MHPA), a technology developed by Emory medical scientists ... MHPA is designed to quickly and reliably determine ...
... you know a,Champion?, The Champions of Health ... Oklahoma,s health. The 2008 Champions of,Health awards program ... difference in the health of Oklahomans. Nominations will ... Nominations can be submitted online at the ...
... Best Practices, LLC,conducted this study report on ... companies across various industries to measure,the performance of ... number of sales calls is most commonly,used to ... year over year account revenue growth as the ...
... down source of salmonella-contaminated tomatoes , , THURSDAY, June ... of salmonella-contaminated tomatoes as a backdrop, Congressional investigators ... Administration has failed to meet its own stated ... Investigators for the Government Accountability Office (GAO) were ...
... ... Development Center, ABBOTT PARK, Ill., June ... Formulation Development Center at the,company,s headquarters in Abbott Park, Ill. The ... have the potential to treat cancer and other deadly diseases. The,center,s ...
Cached Medicine News:Health News:Weight Watchers Declares Quarterly Dividend 2Health News:Syntermed licenses Emory imaging technology for improved evaluation of heart failure patients 2Health News:Nominations Accepted for 2008 'Champions of Health' Awards 2Health News:Benchmarking Study Report on Sales Performance Management 2Health News:Congressional Report Criticizes FDA for Food Safety 2Health News:Congressional Report Criticizes FDA for Food Safety 3Health News:Congressional Report Criticizes FDA for Food Safety 4Health News:Congressional Report Criticizes FDA for Food Safety 5Health News:Abbott Opens New State-of-the-Art R&D Facility to Help Bring Medicines to Patients Faster 2Health News:Abbott Opens New State-of-the-Art R&D Facility to Help Bring Medicines to Patients Faster 3
... PelviSoft® Acellular Collagen BioMesh, provides ... tissue together with the porosity of ... for use in pelvic floor reconstruction. ... and cystocele prolapse, where plication alone ...
... Allograft meets the demanding ... floor reconstructive procedures, and ... suture pull-through, demonstrating long-term ... a structural support for ...
The High Pure Viral RNA Kit is intended for general laboratory use and is designed to purify viral RNA from serum or plasma. Viral RNA is used for RT-PCR analysis directly after elution in nuclease-f...
... The QIAamp Viral RNA Mini ... nucleic acids from cell-free fluid ... acids that can be isolated ... are not limited to, RNA ...
Medicine Products: